Your dentist might be saving your heart, too. New research presented at the American Heart Association's 2026 Scientific Sessions found that Porphyromonas gingivalis — the bacteria behind gum disease — may accumulate in the aortic valve, triggering inflammation and calcium buildup that leads to calcific aortic valve stenosis (CAVS). The findings are preliminary but open a promising new avenue for preventing a condition that currently has no approved medications to slow its progression.
Your dentist might be saving your heart, too. New preliminary research presented at the American Heart Association's Basic Cardiovascular Sciences Scientific Sessions 2026 suggests that Porphyromonas gingivalis — the bacterium primarily responsible for gum disease — may also play a role in calcific aortic valve stenosis (CAVS), a common and potentially life-threatening heart valve disorder. Researchers found significantly higher levels of this bacterium in calcified aortic valves from CAVS patients compared to valves from patients with other heart conditions.
In mouse experiments, repeated exposure to live P. gingivalis led to bacterial accumulation in the aortic valve, increased calcification, and symptoms of aortic stenosis. The bacterium appeared to work by activating interleukin-1 beta (IL-1β), an inflammation-promoting protein. Notably, preventive antibiotics reduced these effects, and genetically removing IL-1β significantly cut valve calcification — even in the presence of the bacteria.
Key Takeaways:
Why it matters: CAVS is one of the most common forms of heart valve disease, and valve replacement surgery remains the only treatment for severe cases. If the oral-cardiac link is confirmed in human clinical trials — which the team has already launched — managing gum health could become a meaningful preventive strategy.
